Dronedarone
- Generic Name
- Dronedarone
- Brand Names
- Multaq
- Drug Type
- Small Molecule
- Chemical Formula
- C31H44N2O5S
- CAS Number
- 141626-36-0
- Unique Ingredient Identifier
- JQZ1L091Y2
- Background
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thrombo...
- Indication
Dronedarone is indicated for the management of atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF to reduce the risk of hospitalization.
- Associated Conditions
- Atrial Fibrillation
- Associated Therapies
- -
Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 154
- Registration Number
- NCT01199081
- Locations
- 🇨🇿
Investigational Site Number 203001, Praha 2, Czech Republic
🇫🇷Investigational Site Number 250-003, Chambray Les Tours Cedex, France
🇩🇪Investigational Site Number 276-002, Chemnitz, Germany
SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 33
- Registration Number
- NCT01182376
Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3236
- Registration Number
- NCT01151137
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 402
- Registration Number
- NCT01140581
- Locations
- 🇦🇹
Investigational Site Number 040-005, Wien, Austria
🇩🇪Investigational Site Number 276-001, Bonn, Germany
🇦🇹Investigational Site Number 040-004, Wien, Austria
Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 112
- Registration Number
- NCT01135017
- Locations
- 🇺🇸
Investigational Site Number 840021, Riverside, California, United States
🇺🇸Investigational Site Number 840030, Mesa, Arizona, United States
🇺🇸Investigational Site Number 840014, Dallas, Texas, United States
Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2010-02-22
- Lead Sponsor
- Eastbourne General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01070667
- Locations
- 🇬🇧
Eastbourne DGH, Eastbourne, East Sussex, United Kingdom
Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 183
- Registration Number
- NCT01047566
- Locations
- 🇳🇱
Sanofi-Aventis Administrative Office, PE Gouda, Netherlands
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 292
- Registration Number
- NCT01026090
- Locations
- 🇨🇦
Investigational Site Number 1240002, Ste-Foy, Canada
🇨🇦Investigational Site Number 1240018, Newmarket, Canada
🇨🇦Investigational Site Number 1240012, Niagara Falls, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.